Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace Biosciences's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 61.03.
Interpace Biosciences's Days Inventory for the
three
months ended in Jun. 2026 was 26.79.
Interpace Biosciences's Days Payable for the
three
months ended in Jun. 2026 was 30.92.
Therefore, Interpace Biosciences's Cash Conversion Cycle (CCC) for the
three
months ended in Jun. 2026 was 56.90.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Interpace Biosciences Cash Conversion Cycle Related Terms
Interpace Biosciences Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PF42 vs PRPO, ADVB, BIOQ: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Interpace Biosciences's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (STU:PF42) has a Cash Conversion Cycle of 56.90 as of Jun. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Interpace Biosciences and its competitors.
Is Interpace Biosciences' Cash Conversion Cycle too high?
Interpace Biosciences' current Cash Conversion Cycle is 56.90. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 70.16. Interpace Biosciences' value of 56.90 is 18.9% below this industry median. Overall, Interpace Biosciences has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Cash Conversion Cycle compare to PRPO and ADVB?
Interpace Biosciences' Cash Conversion Cycle of 56.90 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 70.16. Interpace Biosciences' value of 56.90 is 18.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 70.16, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current Cash Conversion Cycle of 56.90 is 18.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 70.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current Cash Conversion Cycle is 56.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Interpace Biosciences (STU:PF42) has a current Cash Conversion Cycle of 56.90. The stock's GF Value™ is €0.17, compared to a current price of €1.34 — trading 688.2% above its estimated fair value. The current Cash Conversion Cycle is 56.90 and 18.9% below the Medical Diagnostics & Research industry median of 70.16. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Interpace Biosciences (STU:PF42), the current Cash Conversion Cycle is 56.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (STU:PF42) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of €1.34 is trading 688.2% above its estimated GF Value™ of €0.17.
Key valuation signals for STU:PF42:
Cash Conversion Cycle: 56.90
GF Value™: €0.17 vs. price of €1.34 (688.2% above fair value)
Industry Position: 18.9% below the Medical Diagnostics & Research median
No single metric tells the full story. See the STU:PF42 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for STU:PF42
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PF42 has been successfully added to your 
